sun pharma - Latest News, Analysis, Opinion

‘We are meticulously nurturing the specialty business and have built a portfolio of about 10 specialty products’

Sun Pharma Tumbles After Report Of Probe

Markets regulator Securities and Exchange Board of India (SEBI) is likely to reopen an insider trading case against Sun, media sources reported

Sensex Rebounds On Value-Buying In Beaten Down Stocks, RIL Leads Recovery

Companies & Markets Markets Stock Market

BSE Sensex recovered at 224.50 points to end at 38,242.81 on value buying in hammered stocks led by RIL and Sun Pharma

The Fight Is On

Himani Chandna

Companies & Markets Sector Reports

Sun Pharma’s Dilip Shanghvi is all set to conquer the new normal

Market Moves With Caution, RBI Rate Call Takes Centre-stage

PTI

Companies & Markets Markets Stock Market

Major stocks that rose include Sun Pharma, PowerGrid, Dr Reddy's and RIL, jumping up to 3.47 per cent

Liquidity Worries Haunt Stocks, Sensex, Nifty Stay Soft

Economy India

The mood at the outset was one of bullishness, given a gap-up opening, but bears took charge during the last half an hour of trade

Sun Pharma Reports Quarterly Loss After One-off Charge

The net loss was 4.25 billion rupees ($66 million) in the three months ending on June 30, compared with a profit of 20.34 billion rupees a year earlier

No More Freebies: India Plans Crackdown On Marketing By Drugmakers

Healthcare Healthcare

While such rules are common elsewhere in the world and adhered to by large pharmaceutical companies, they are not set in stone in India, where campaigners have long demanded a crackdown on unethical selling practices

Is It The End Of Pharma’s Dream Run?

Himani Chandna

Unless the Indian pharma industry — not long ago touted as the pharmacy of the world — strives to be more than just a plain generics player

Worst Ever Quarter For Indian Pharma

Top drug makers such as Sun Pharmaceutical Industries, Dr Reddy’s Laboratories and Cadila Healthcare faced US import ban on their key production facilities in India

Sun Pharma Buys Novartis’ Anti-cancer Brand Odomzo For $175 Million

Reason for selling this new anti-cancer drug by Novartis, which consolidated its global oncology business by acquiring the entire cancer drug portfolio of GlaxoSmithKline (GSK) in a $16 billion global deal in March 2015, is not disclosed

Sun Pharma Buys Russian Drug Maker JSC Biosintez

JSC is currently engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region mainly focusing on the hospital segment had annual revenues of approximately $ 52 million in 2015

Sun Pharma Completes Rs 675-crore Share Buyback

As per Sebi guidelines, 15 per cent of the buyback offer is reserved for shareholders holding shares having a market value of not more than Rs 2,00,000 as on the record date

Mockery Of Corporate Governance: The Sun Pharma Way